Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis.

Respiratory Research
Kakuhiro YamaguchiNoboru Hattori

Abstract

The endogenous secretory receptor for advanced glycation end products (esRAGE) is a soluble isoform produced by alternative splicing of the RAGE gene. The isoform has anti-inflammatory properties due to its inhibition of the RAGE/ligand interaction and is reduced in the lung tissue of patients with idiopathic pulmonary fibrosis (IPF). This study aimed to investigate the association of esRAGE serum and bronchoalveolar lavage fluid (BALF) levels with progression of IPF. This study included 79 IPF patients and 90 healthy controls. IPF and control serum esRAGE levels were compared, and the correlation between serum and BALF esRAGE levels was analyzed in 57 IPF patient samples. We also investigated the relationship of esRAGE serum and BALF levels with prognoses and lung function parameters in patients with IPF. Serum esRAGE levels in IPF patients were significantly lower than those in healthy controls (162.0 ± 102.4 ng/ml and 200.7 ± 107.3 ng/ml, p = 0.009), although the baseline characteristics of age and smoking history were not matched. Serum levels of esRAGE were correlated with BALF esRAGE levels (rs = 0.317). The BALF esRAGE levels were also correlated with diffusion capacity for carbon monoxide (rs = 0.406). A Kaplan-Meier cu...Continue Reading

References

May 30, 2003·American Journal of Respiratory and Critical Care Medicine·Harold R CollardKevin K Brown
Jun 7, 2003·American Journal of Respiratory and Critical Care Medicine·Panagiota I LatsiAthol U Wells
Jun 19, 2004·American Journal of Respiratory Cell and Molecular Biology·Katherine DahlinLeland Dobbs
Jul 5, 2005·The European Respiratory Journal·M R MillerUNKNOWN ATS/ERS Task Force
Aug 31, 2006·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Patrizia MorbiniMaurizio Luisetti
Dec 20, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Barry I HudsonAnn Marie Schmidt
Feb 5, 2008·The American Journal of Pathology·Judson M EnglertTim D Oury
Apr 29, 2008·American Journal of Respiratory Cell and Molecular Biology·Naoki HamadaYoichi Nakanishi
Apr 14, 2009·American Journal of Respiratory and Critical Care Medicine·Kazuhisa KonishiNaftali Kaminski
Feb 11, 2010·Journal of Biomedicine & Biotechnology·Stephen T Buckley, Carsten Ehrhardt
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
Jul 2, 2011·Lancet·Talmadge E KingMoisés Selman
Feb 26, 2014·Respiratory Research·Poornima GopalErica P A Rutten
Apr 25, 2014·BMC Pulmonary Medicine·Hiroshi IwamotoWitold Mazur
Feb 16, 2017·Respirology : Official Journal of the Asian Pacific Society of Respirology·Kakuhiro YamaguchiNoboru Hattori
Mar 2, 2017·Annals of the American Thoracic Society·Ani ManichaikulDavid J Lederer
Nov 10, 2018·Respiratory Research·Carlos MachahuaVanesa Vicens-Zygmunt
Jul 5, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Kakuhiro YamaguchiNoboru Hattori
Aug 16, 2019·Respiration; International Review of Thoracic Diseases·Masako WatanabeNoboru Hattori

❮ Previous
Next ❯

Citations

Jul 20, 2021·Therapeutic Advances in Respiratory Disease·Timothy N Perkins, Tim D Oury
Jan 11, 2022·The Clinical Respiratory Journal·Daniel S GlassAllison B Reiss

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar lavage
biopsies
enzyme-linked immunosorbent assay
PCR
Genotyping
bronchoalveolar
lavage

Software Mentioned

JMP

Related Concepts

Related Feeds

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Alternative splicing

Alternative splicing a regulated gene expression process that allows a single genetic sequence to code for multiple proteins. Here is that latest research.